In 458 Japanese adults with migraine in an uncontrolled open-label extension of a phase 3 trial, monthly migraine days on rimegepant 75 mg fell by a mean 4.5 vs the observation period; 1.3% stopped for adverse events and 0.9% had serious adverse events.
RCTn = 458
Matsumori et al. Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study